Hikma Pharmaceutical (HKMPF) 31.2000 $HKMPF
Hikma Pharmaceuticals Announces it Received a Warning Letter from Federal Regulators Over Significant Issues Discovered at Portugal Plant, Parker Waichman LLP Comments
PRWeb - Thu Nov 13, 11:04AM CST
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medications, comments on an October 24, 2014 Hikma Pharmaceuticals' announcement that the multinational pharmaceutical group received a Warning Letter from the U.S. Food and Drug Administration (FDA) concerning an inspection that took place at its Portugal manufacturing facility in March 2014.
Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors
Marketwired - Tue Oct 21, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors.
Abscess Market Analysis 2014-2015: API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xv2wdj/abscess_market) has announced the addition of the "Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Abscess Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pfizer Inc. - Astellas Pharma Inc. - B. Braun Medical Inc. - Actavis, Inc. - Hospira, Inc. - Hikma Pharmaceuticals PLC - Sandoz Inc. - Mutual Pharmaceutical Company, Inc. - Par Pharmaceutical Companies, Inc. - Pharmacia & Upjohn, Inc. - Mission Pharmacal Company - Baxter Healthcare Corporation - Abbott Laboratories - B. Braun Avitum AG - LNK International Inc. For more information visit http://www.researchandmarkets.com/research/xv...ess_market
ABT: 45.70 (-0.02), ACT: 254.20 (-1.68), PFE: 31.42 (-0.03)
Earnings Release Schedules, GIPS Accreditation, Project Updates, and Regulatory Disclosures - Analyst Notes on Hikma, Rathbone, Rotork, Bank of Georgia and Coca Cola HBC
PR Newswire Europe - Fri Jun 27, 12:11AM CDT
LONDON, June 27, 2014 /PRNewswire/ --
CCH: 23.33 (-0.26)
Hikma Pharmaceuticals Announces it Received a Warning Letter from Federal Regulators Over Significant Issues Discovered at Portugal Plant, Parker Waichman LLP Comments
PRWeb - Thu Nov 13, 11:04AM CST
Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims who have been injured by medications, comments on an October 24, 2014 Hikma Pharmaceuticals' announcement that the multinational pharmaceutical group received a Warning Letter from the U.S. Food and Drug Administration (FDA) concerning an inspection that took place at its Portugal manufacturing facility in March 2014.
Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors
Marketwired - Tue Oct 21, 7:30AM CDT
Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), announces that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors.
Abscess Market Analysis 2014-2015: API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xv2wdj/abscess_market) has announced the addition of the "Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Abscess Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pfizer Inc. - Astellas Pharma Inc. - B. Braun Medical Inc. - Actavis, Inc. - Hospira, Inc. - Hikma Pharmaceuticals PLC - Sandoz Inc. - Mutual Pharmaceutical Company, Inc. - Par Pharmaceutical Companies, Inc. - Pharmacia & Upjohn, Inc. - Mission Pharmacal Company - Baxter Healthcare Corporation - Abbott Laboratories - B. Braun Avitum AG - LNK International Inc. For more information visit http://www.researchandmarkets.com/research/xv...ess_market
ABT: 45.70 (-0.02), ACT: 254.20 (-1.68), PFE: 31.42 (-0.03)
Earnings Release Schedules, GIPS Accreditation, Project Updates, and Regulatory Disclosures - Analyst Notes on Hikma, Rathbone, Rotork, Bank of Georgia and Coca Cola HBC
PR Newswire Europe - Fri Jun 27, 12:11AM CDT
LONDON, June 27, 2014 /PRNewswire/ --
CCH: 23.33 (-0.26)
